MX337477B - Derivados de diaminopiridina y procesos para su preparacion. - Google Patents

Derivados de diaminopiridina y procesos para su preparacion.

Info

Publication number
MX337477B
MX337477B MX2013009549A MX2013009549A MX337477B MX 337477 B MX337477 B MX 337477B MX 2013009549 A MX2013009549 A MX 2013009549A MX 2013009549 A MX2013009549 A MX 2013009549A MX 337477 B MX337477 B MX 337477B
Authority
MX
Mexico
Prior art keywords
preparation
pharmaceutically acceptable
acceptable salt
processes
diaminopyrimidine derivative
Prior art date
Application number
MX2013009549A
Other languages
English (en)
Other versions
MX2013009549A (es
Inventor
Hyun-Joo Lee
Dong-Hoon Kim
Tae-Kyun Kim
Young-Ae Yoon
Jae-Young Sim
Myung-Hun Cha
Eun-Jung Jung
Kyoung-Kyu Ahn
Tai-Au Lee
Original Assignee
Yuhan Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yuhan Corp filed Critical Yuhan Corp
Publication of MX2013009549A publication Critical patent/MX2013009549A/es
Publication of MX337477B publication Critical patent/MX337477B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención proporciona un derivado de diaminopirimidina o su sal farmacéutica aceptable, un proceso para su preparación, una composición farmacéutica que lo comprende y el uso de los mismos. El derivado de diaminopirimidina o su sal farmacéutica aceptable funciona como un receptor 5-HT4 y por tanto puede aplicarse en forma útil para evitar o tratar disfunción en movilidad gastrointestinal, una de las enfermedades gastrointestinales, tales como enfermedad de reflujo gastroesofágico (GERD), constipación, síndrome de intestino irritable (lBS), dispepsia, íleo post-operativo, vaciado gástrico retrasado, gastroparesis, pseudo-obstrucción intestinal, tránsito retrasado inducido por fármaco, o atonía gástrica diabética.
MX2013009549A 2011-02-25 2012-02-24 Derivados de diaminopiridina y procesos para su preparacion. MX337477B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20110016981 2011-02-25
PCT/KR2012/001427 WO2012115480A2 (en) 2011-02-25 2012-02-24 Diaminopyrimidine derivatives and processes for the preparation thereof

Publications (2)

Publication Number Publication Date
MX2013009549A MX2013009549A (es) 2013-09-06
MX337477B true MX337477B (es) 2016-03-07

Family

ID=46721361

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2013009627A MX336155B (es) 2011-02-25 2012-02-24 Derivados de diaminopirimidina y procesos para su preparacion.
MX2013009549A MX337477B (es) 2011-02-25 2012-02-24 Derivados de diaminopiridina y procesos para su preparacion.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2013009627A MX336155B (es) 2011-02-25 2012-02-24 Derivados de diaminopirimidina y procesos para su preparacion.

Country Status (17)

Country Link
US (4) US9850227B2 (es)
EP (2) EP2678331B1 (es)
JP (2) JP5890436B2 (es)
KR (2) KR101671341B1 (es)
CN (2) CN103402997B (es)
AU (2) AU2012221925B2 (es)
BR (2) BR112013019942B1 (es)
CA (2) CA2827072C (es)
DK (1) DK2678332T3 (es)
ES (2) ES2587304T3 (es)
HU (1) HUE029988T2 (es)
IN (1) IN2013MN01519A (es)
MX (2) MX336155B (es)
PL (2) PL2678331T3 (es)
PT (1) PT2678332T (es)
RU (1) RU2587493C2 (es)
WO (2) WO2012115478A2 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE029988T2 (en) * 2011-02-25 2017-04-28 Yuhan Corp Diaminopyrimidine derivatives and processes for their preparation
CA2892045C (en) 2012-11-21 2022-05-31 Ptc Therapeutics, Inc. Substituted reverse pyrimidine bmi-1 inhibitors
KR101657616B1 (ko) * 2013-05-24 2016-09-19 주식회사유한양행 피리미딘 고리를 포함하는 바이사이클릭 유도체 및 그의 제조방법
AU2013399092A1 (en) 2013-08-30 2016-03-17 Ptc Therapeutics, Inc. Substituted pyrimidine Bmi-1 inhibitors
EP3071553A4 (en) 2013-11-21 2017-08-02 PTC Therapeutics, Inc. Substituted pyridine and pyrazine bmi-1 inhibitors
CN104003944B (zh) * 2014-05-29 2016-08-24 西北师范大学 一种嘧菌胺的制备方法
PT3604294T (pt) * 2014-10-13 2021-07-29 Yuhan Corp Compostos e composições para modular atividades da cinase do mutante de egfr
US10300155B2 (en) 2015-12-31 2019-05-28 Washington University Alpha-synuclein ligands
CN105646321A (zh) * 2016-01-07 2016-06-08 中国药科大学 (s)-3-羟基吡咯烷盐酸盐的制备方法
GB201604647D0 (en) 2016-03-18 2016-05-04 Mission Therapeutics Ltd Novel compounds
KR102441327B1 (ko) * 2018-05-18 2022-09-07 주식회사유한양행 다이아미노피리미딘 유도체 또는 이의 산부가염의 신규의 제조방법
WO2020055544A2 (en) 2018-08-17 2020-03-19 Ptc Therapeutics, Inc. Method for treating pancreatic cancer
CN118834204A (zh) 2018-12-18 2024-10-25 阿斯利康(瑞典)有限公司 制药方法和中间体
CN110317176A (zh) * 2019-07-04 2019-10-11 沈阳药科大学 2-氨基嘧啶类化合物及其用途
KR20220006776A (ko) * 2020-07-09 2022-01-18 주식회사유한양행 다이아미노피리미딘 유도체 또는 이의 약학적으로 허용가능한 염을 포함하는 약학 조성물 및 이의 제조방법
WO2025104079A1 (en) * 2023-11-17 2025-05-22 Helmholtz-Zentrum für Infektionsforschung GmbH Salicylic acid and picolinic acid derivatives as inhibitors of energy coupling factor (ecf) transporters for the treatment of bacterial infections

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4962115A (en) 1981-10-01 1990-10-09 Janssen Pharmaceutica N.V. Novel N-(3-hydroxy-4-piperidinyl)benzamide derivatives
SK279058B6 (sk) 1986-04-30 1998-06-03 Dainippon Pharmaceutical Co. Substituovaný n-[(2-morfolynyl)alkyl]banzamidový d
GB9005014D0 (en) 1990-03-06 1990-05-02 Janssen Pharmaceutica Nv N.(4.piperidinyl)(dihydrobenzofuran or dihydro.2h.benzopyran)carboxamide derivatives
HUT64023A (en) 1991-03-22 1993-11-29 Sandoz Ag Process for producing aminoguanidine derivatives and pharmaceutical compositions comprising such compounds
CZ101496A3 (en) * 1993-10-12 1996-11-13 Du Pont Merck Pharma N-alkyl-n-aryl-pyrimidinamines and derivatives thereof
WO1995010506A1 (en) * 1993-10-12 1995-04-20 The Du Pont Merck Pharmaceutical Company 1n-alkyl-n-arylpyrimidinamines and derivatives thereof
IL112024A (en) * 1993-12-21 1999-07-14 Novo Nordisk As Pharmaceutical compositions comprising tetrahydropyridine derivatives substituted with oxadiazole or thiadiazole for treating gastrointestinal motility disorders
JP2896532B2 (ja) * 1994-08-13 1999-05-31 ユーハン コーポレーション 新規なピリミジン誘導体およびその製造方法
US5739151A (en) * 1996-07-19 1998-04-14 Sepracor Inc. Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride
IN188411B (es) 1997-03-27 2002-09-21 Yuhan Corp
US6825198B2 (en) * 2001-06-21 2004-11-30 Pfizer Inc 5-HT receptor ligands and uses thereof
US7722893B2 (en) 2003-07-25 2010-05-25 Ciba Specialty Chemicals Corporation Use of substitute 2,4-bis (alkylamino) pyrimidines or quinzolines as antimicrobials
KR20060118421A (ko) * 2003-08-29 2006-11-23 다이노젠 파마세우티컬스, 인코포레이티드 위장 운동 장애의 치료에 유용한 조성물
US20060057972A1 (en) 2004-09-14 2006-03-16 Wikel Harold L Adapter for a modular wireless communication device
US20060128726A1 (en) 2004-11-24 2006-06-15 Xuebao Wang Process for preparing novel crystalline forms of (2S)-1-[[(7R)-7-(3,4-dichlorophenyl)-4,7-dihydro-5-methylpyrazolo[1,5]pyrimidine-6-yl]carbonyl]-2-(4-fluorophenyl)pyrrolidine, novel stable forms produced therein and formulations
ES2523459T3 (es) * 2005-02-25 2014-11-26 Raqualia Pharma Inc Derivados de benzisoxazol
US20070032514A1 (en) * 2005-07-01 2007-02-08 Zahn Stephan K 2,4-diamino-pyrimidines as aurora inhibitors
US20080293942A1 (en) * 2005-11-28 2008-11-27 Cousins Russell D Methods of Preparing 2-Imidazol-1-Yl-4-Methyl-6-Pyrrolidin-2-Yl-Pyrimidine and 4-(1-Alkylpyrrolidin-2-Yl)-2-(1H-Imidazol-1-Yl)-6-Methylpyrimidine Derivatives
EP2003131A4 (en) * 2006-04-04 2009-12-16 Taisho Pharmaceutical Co Ltd AMINOPYRROLIDINE COMPOUND
EP2007754A1 (en) * 2006-04-10 2008-12-31 Boehringer Ingelheim International GmbH 2, 4-diaminopyrimidine derivatives and their use for the treatment of cancer
WO2009103652A1 (en) * 2008-02-22 2009-08-27 F. Hoffmann-La Roche Ag Modulators for amyloid beta
CA2760794C (en) * 2009-05-05 2017-07-25 Dana Farber Cancer Institute Egfr inhibitors and methods of treating disorders
HUE029988T2 (en) * 2011-02-25 2017-04-28 Yuhan Corp Diaminopyrimidine derivatives and processes for their preparation

Also Published As

Publication number Publication date
US20130338179A1 (en) 2013-12-19
WO2012115478A3 (en) 2012-10-18
KR20120098483A (ko) 2012-09-05
KR101671348B1 (ko) 2016-11-01
KR101671341B1 (ko) 2016-11-01
PL2678331T3 (pl) 2016-12-30
PT2678332T (pt) 2016-08-22
DK2678332T3 (en) 2016-08-15
ES2579830T3 (es) 2016-08-17
US9850227B2 (en) 2017-12-26
JP2014506591A (ja) 2014-03-17
JP5890436B2 (ja) 2016-03-22
MX2013009627A (es) 2014-02-17
CN103391935B (zh) 2015-12-23
CN103402997A (zh) 2013-11-20
EP2678331B1 (en) 2016-04-27
EP2678332A2 (en) 2014-01-01
JP2014506592A (ja) 2014-03-17
CA2827072C (en) 2019-01-08
BR112013020641B1 (pt) 2021-11-03
AU2012221925B2 (en) 2016-05-05
HUE029988T2 (en) 2017-04-28
US20180072705A1 (en) 2018-03-15
BR112013019942B1 (pt) 2022-01-11
WO2012115480A3 (en) 2012-10-18
AU2012221927B2 (en) 2016-04-28
US20180111918A1 (en) 2018-04-26
WO2012115480A2 (en) 2012-08-30
IN2013MN01519A (es) 2015-06-12
MX336155B (es) 2016-01-07
EP2678332A4 (en) 2014-07-23
EP2678331A4 (en) 2014-07-30
RU2013142187A (ru) 2015-03-27
EP2678332B1 (en) 2016-05-18
WO2012115478A2 (en) 2012-08-30
RU2013142188A (ru) 2015-03-27
JP5980236B2 (ja) 2016-08-31
US20150274700A2 (en) 2015-10-01
US20130331377A1 (en) 2013-12-12
RU2587493C2 (ru) 2016-06-20
ES2587304T3 (es) 2016-10-21
CA2827072A1 (en) 2012-08-30
CA2827030A1 (en) 2012-08-30
BR112013019942A2 (pt) 2018-08-14
EP2678331A2 (en) 2014-01-01
US9890138B2 (en) 2018-02-13
HK1188215A1 (en) 2014-04-25
PL2678332T3 (pl) 2016-12-30
US10227330B2 (en) 2019-03-12
CN103402997B (zh) 2015-08-26
MX2013009549A (es) 2013-09-06
BR112013020641A2 (pt) 2016-10-18
CA2827030C (en) 2019-01-08
KR20120098484A (ko) 2012-09-05
HK1188214A1 (zh) 2014-04-25
US10640490B2 (en) 2020-05-05
CN103391935A (zh) 2013-11-13

Similar Documents

Publication Publication Date Title
MX337477B (es) Derivados de diaminopiridina y procesos para su preparacion.
WO2012115479A3 (en) Diaminopyrimidine derivatives and processes for the preparation thereof
WO2008021849A3 (en) Novel compounds as antagonists or inverse agonists at opioid receptors
CL2007002499A1 (es) Sales citrato y tartrato de compuestos derivados de acido pirrolidinilaminoacetilpirrolidinboronico, inhibidores de dpp-iv; metodo de preparacion; forma solida; combinacion farmaceutica, util para el tratamiento de diabetes.
EA201290254A1 (ru) Антагонисты il-17a
EP4268814A3 (en) Pharmaceutical composition for the treatment of dry eye
HUP0600810A3 (en) New sulfonamide derivatives as bradykinin antagonists, process and intermediates for their preparation and pharmaceutical compositions containing them
WO2010123930A3 (en) Chemosensory receptor ligand-based therapies
AU2009301431A8 (en) Bispecific anti-VEGF/anti-ANG-2 antibodies
WO2007150025A3 (en) Purinone derivatives as hm74a agonists
MX2010008375A (es) Derivados de piperidina espirocíclicos substituidos como ligandos de receptores de histamina-3 (h3).
WO2006104826A3 (en) Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
EA201190319A1 (ru) Твердая фармацевтическая композиция, содержащая ривароксабан
PL2084543T3 (pl) Stratyfikacja ryzyka ostrego zespołu wieńcowego za pomocą fragmentów/ częściowych peptydów prowazopresyny, a zwłaszcza kopeptyny lub neurofizyny II
IL195514A (en) Converted Pyridyl Compounds
WO2010001257A3 (en) Novel solid state forms of laquinimod and its sodium salt
WO2011045232A3 (en) Neuropeptide-2 receptor (y-2r) agonists
WO2010052144A3 (en) Neuropeptide-2-receptor (y-2r) agonists and uses thereof
EA201370219A1 (ru) Противогипертоническая фармацевтическая композиция
WO2010049449A3 (en) Novel salts of sunitinib
EA201171307A1 (ru) Антагонисты толл-подобного рецептора 3
HUP0600809A2 (en) New phenylsulfamoyl-benzamide derivatives as bradykinin antagonists, process and intermediates for their preparation and pharmaceutical compositions containing them
Rzasa et al. Synthesis and preliminary biological evaluation of potent and selective 2-(3-alkoxy-1-azetidinyl) quinolines as novel PDE10A inhibitors with improved solubility
EA201001870A1 (ru) Новые кристаллические формы рабепразола натрия
WO2013175499A3 (en) Process for the preparation of 5-(4-[4-(5-cyano-1 h-indol-3-yl)butyl]piperazin-1 -yl)benzofuran-2-carboxamide and intermediates thereof, polymorphic forms thereof

Legal Events

Date Code Title Description
FG Grant or registration